Keros Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Keros Therapeutics, Inc. (KROS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$28.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-03
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$28.71M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$23.71M, a 115.97% decline year-over-year.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$23.46M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$7.28M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $87.01M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$187.35M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$152.99M.
- Keros Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$104.68M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.71M 10-Q · filed 2026-08-03 | -$52.42M 10-Q · filed 2026-08-03 | -$75.88M derived: sum of 3 quarters · filed 2026-08-03 | -$83.16M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$23.71M 10-Q · filed 2026-05-14 | -$47.17M derived: sum of 2 quarters · filed 2026-05-14 | -$54.45M derived: sum of 3 quarters · filed 2026-05-14 | -$85.14M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$23.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$30.74M derived: sum of 2 quarters · filed 2026-03-04 | -$61.44M derived: sum of 3 quarters · filed 2026-08-03 | $87.01M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$7.28M 10-Q · filed 2025-11-05 | -$37.98M derived: sum of 2 quarters · filed 2026-08-03 | $110.47M 10-Q · filed 2025-11-05 | $64.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$30.70M 10-Q · filed 2026-08-03 | $117.75M 10-Q · filed 2026-08-03 | $71.73M derived: sum of 3 quarters · filed 2026-08-03 | $18.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $148.45M 10-Q · filed 2026-05-14 | $102.42M derived: sum of 2 quarters · filed 2026-05-14 | $49.47M derived: sum of 3 quarters · filed 2026-05-14 | $4.21M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$46.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$98.98M derived: sum of 2 quarters · filed 2026-03-04 | -$144.24M derived: sum of 3 quarters · filed 2026-03-04 | -$187.35M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$52.96M 10-Q · filed 2025-11-05 | -$98.21M derived: sum of 2 quarters · filed 2025-11-05 | -$141.33M 10-Q · filed 2025-11-05 | -$181.57M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$45.26M 10-Q · filed 2025-08-06 | -$88.37M 10-Q · filed 2025-08-06 | -$128.61M derived: sum of 3 quarters · filed 2025-08-06 | -$168.05M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$43.11M 10-Q · filed 2025-05-06 | -$83.36M derived: sum of 2 quarters · filed 2025-05-06 | -$122.80M derived: sum of 3 quarters · filed 2025-05-06 | -$160.30M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$40.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$79.68M derived: sum of 2 quarters · filed 2025-02-26 | -$117.19M derived: sum of 3 quarters · filed 2025-02-26 | -$152.99M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$39.44M 10-Q · filed 2024-11-06 | -$76.94M derived: sum of 2 quarters · filed 2024-11-06 | -$112.75M 10-Q · filed 2024-11-06 | -$142.47M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$37.51M 10-Q · filed 2024-08-07 | -$73.31M 10-Q · filed 2024-08-07 | -$103.03M derived: sum of 3 quarters · filed 2025-02-26 | -$126.54M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$35.80M 10-Q · filed 2024-05-08 | -$65.52M derived: sum of 2 quarters · filed 2025-02-26 | -$89.03M derived: sum of 3 quarters · filed 2025-02-26 | -$116.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$29.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$53.23M derived: sum of 2 quarters · filed 2025-02-26 | -$80.49M derived: sum of 3 quarters · filed 2025-02-26 | -$104.68M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$23.51M 10-Q · filed 2023-11-06 | -$50.77M derived: sum of 2 quarters · filed 2023-11-06 | -$74.96M 10-Q · filed 2023-11-06 | -$81.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$27.27M 10-Q · filed 2023-08-07 | -$51.45M 10-Q · filed 2023-08-07 | -$58.39M derived: sum of 3 quarters · filed 2024-02-28 | -$78.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$24.19M 10-Q · filed 2023-05-04 | -$31.13M derived: sum of 2 quarters · filed 2024-02-28 | -$51.42M derived: sum of 3 quarters · filed 2024-02-28 | -$67.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$27.24M derived: sum of 2 quarters · filed 2024-02-28 | -$42.86M derived: sum of 3 quarters · filed 2024-02-28 | -$58.74M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$20.30M 10-Q · filed 2022-11-03 | -$35.92M derived: sum of 2 quarters · filed 2022-11-03 | -$51.80M 10-Q · filed 2022-11-03 | -$61.47M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$15.62M 10-Q · filed 2022-08-04 | -$31.51M 10-Q · filed 2022-08-04 | -$41.17M derived: sum of 3 quarters · filed 2022-08-04 | -$53.21M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$15.88M 10-Q · filed 2022-05-05 | -$25.55M derived: sum of 2 quarters · filed 2022-05-05 | -$37.59M derived: sum of 3 quarters · filed 2022-05-05 | -$48.55M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$9.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$21.70M derived: sum of 2 quarters · filed 2022-03-09 | -$32.66M derived: sum of 3 quarters · filed 2022-03-09 | -$45.36M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$12.04M 10-Q · filed 2021-11-04 | -$23.00M derived: sum of 2 quarters · filed 2021-11-04 | -$35.70M 10-Q · filed 2021-11-04 | -$38.90M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$10.96M 10-Q · filed 2021-08-05 | -$23.66M 10-Q · filed 2021-08-05 | -$26.86M derived: sum of 3 quarters · filed 2021-08-05 | -$30.86M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$12.70M 10-Q · filed 2021-05-06 | -$15.90M derived: sum of 2 quarters · filed 2021-05-06 | -$19.90M derived: sum of 3 quarters · filed 2021-05-06 | -$23.20M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$7.20M derived: sum of 2 quarters · filed 2021-03-25 | -$10.50M derived: sum of 3 quarters · filed 2021-03-25 | -$14.14M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$4.00M 10-Q · filed 2020-11-10 | -$7.30M derived: sum of 2 quarters · filed 2020-11-10 | -$10.94M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$3.30M 10-Q · filed 2020-08-13 | -$6.94M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$3.63M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |